ReviewSocial work in public health2013
Medications for substance use disorders.
Review in Social work in public health, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 3 syntheses or guidelines pooled it, 91 citations in OpenAlex.
- Efficacy of cannabidiol alone or in combination with Δ-9-tetrahydrocannabinol for the management of substance use disorders: An umbrella review of the evidence.Addiction (Abingdon, England) · 2025Pooled it
- Psychosocial and pharmacologic interventions to reduce harmful alcohol use in low- and middle-income countries.The Cochrane database of systematic reviews · 2023Pooled it
- Internet interventions for adult illicit substance users: a meta-analysis.Addiction (Abingdon, England) · 2017Pooled it
- Memantine treatment improves opioid-induced hyperalgesia symptoms: randomize clinical trial.Scientific reports · 2025Trial
- Transition of Patients with Opioid Use Disorder from Buprenorphine to Extended-Release Naltrexone: A Randomized Clinical Trial Assessing Two Transition Regimens.The American journal on addictions · 2020Trial
- Are virtual reality (VR) interventions for substance use disorders designed for implementation? A rapid review of platform characteristics and clinical fit.Research square · 2026Article
- Prevalence of Substance Use in Northwest Syria: A Cross-Sectional Study.International journal of public health · 2026Article
- Microbiome-derived metabolites in substance use disorders: Mechanisms and implications.Annals of the New York Academy of Sciences · 2025Review
- The impact of increased telehealth use on the treatment of substance use disorder during the COVID-19 pandemic.SSM - population health · 2025Article
- Pharmacist administration of long-acting injectable medications for substance use disorders: A scoping review.The mental health clinician · 2025Review
- Neuroscience and addiction research: current advances and perspectives.Journal of neural transmission (Vienna, Austria : 1996) · 2024Article
- Driving innovation in addiction treatment: role of transcranial magnetic stimulation.Journal of neural transmission (Vienna, Austria : 1996) · 2024Review
- Repurposing Drugs for Inhibition against ALDH2 via a 2D/3D Ligand-Based Similarity Search and Molecular Simulation.Molecules (Basel, Switzerland) · 2023Article
- Antidepressant Medication Does Not Contribute to the Elevated Circulating Concentrations of Acylethanolamides Found in Substance Use Disorder Patients.International journal of molecular sciences · 2023Article
- Multiobjective Molecular Optimization for Opioid Use Disorder Treatment Using Generative Network Complex.Journal of medicinal chemistry · 2023Article
- Observational
- Machine-learning repurposing of DrugBank compounds for opioid use disorder.Computers in biology and medicine · 2023Article
- Multi-ancestry transcriptome-wide association analyses yield insights into tobacco use biology and drug repurposing.Nature genetics · 2023Article
- The Evolving Role of Animal Models in the Discovery and Development of Novel Treatments for Psychiatric Disorders.Advances in neurobiology · 2023Article
- Nanoparticle delivery systems for substance use disorder.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
In this article, the authors briefly review the pharmacotherapeutic agents that are currently available for the treatment of substance use disorders. Nicotine replacement therapies are most effective for tobacco cessation. Naltrexone, acamprosate, and disulfiram are effective for reducing alcohol use. The most effective pharmacotherapies for opiate use disorders are agonist therapies, including methadone and buprenorphine. The authors also examine recent advances in medication development for other substance use disorders such as stimulant addiction. The role of medication adherence and behavioral treatments and the integration of behavioral and pharmacotherapeutic interventions are also discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.